U.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults based on induction studies, U-EXCEED, U-EXCEL,& U-ENDURE maintenance study. This is 7th FDA approval for RINVOQ https://t.co/JFyiETe43S https://t.co/zGJKZ3l0d4